Samantha L Ginn
Dr Ginn is a Senior Research Officer in the Gene Therapy Research Unit of the Children’s Medical Research Institute and a Senior Lecturer at the University of Sydney. Her current research uses cutting-edge CRISPR-Cas9 technology and AAV vector delivery systems to correct patient-derived primary human hepatocytes with metabolic liver disease in vivo and currently holds two research grants for genome editing projects using AAV-mediated gene delivery as Chief Investigator. Dr Ginn was a member of the team involved in treating the first infant in Australia with gene therapy and has proven expertise in vector-mediated gene delivery in both primary human cells and small animal models. Dr Ginn holds leadership positions on the Australasian Gene and Cell Therapy Society Executive as their current Secretary and the Asia-Pacific Consortium of Gene and Cell Therapy as a Council Member. She is also an Editorial Board member for the Journal of Gene Medicine.
Abstracts this author is presenting:
